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EssentialsTherapeutic options for the management of VTE in patients with cancer remain limited.Medical and pharmacy claims from the Humana Database were analyzed.LMWH was associated with lower persistence and more switching than warfarin and rivaroxaban.LMWH is at significantly higher risk to discontinue early relative to warfarin and rivaroxaban.

1. INTRODUCTION {#rth212002-sec-0007}
===============

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of death for cancer patients.[1](#rth212002-bib-0001){ref-type="ref"} When compared to the general population, patients with cancer are associated with a 4.1‐fold risk of thrombosis, and the risk increases by 6.5‐fold for those undergoing chemotherapy.[2](#rth212002-bib-0002){ref-type="ref"}, [3](#rth212002-bib-0003){ref-type="ref"} Anticoagulation is key for the treatment and prevention of VTE recurrence. Current guidelines recommend anticoagulation with low--molecular‐weight heparin (LMWH) monotherapy for at least 3‐6 months for treatment and secondary prophylaxis in patients with cancer.[4](#rth212002-bib-0004){ref-type="ref"}, [5](#rth212002-bib-0005){ref-type="ref"} Treatment beyond the initial 6 months should also be considered for patients with metastatic disease or those receiving chemotherapy. These recommendations are based on clinical trials that show superiority of LMWH therapies over vitamin K antagonists (VKAs); however, efficacy superiority reached statistical significance only in one of the clinical trials (the CLOT trial).[6](#rth212002-bib-0006){ref-type="ref"}, [7](#rth212002-bib-0007){ref-type="ref"}, [8](#rth212002-bib-0008){ref-type="ref"}

Vitamin K antagonists, primarily warfarin, are still widely used in clinical practice, but these drugs are difficult to manage in oncology patients: VKAs are associated with many interactions with other drugs and food. These interactions can lead to fluctuations in the international normalized ratio (INR), and despite the need for frequent monitoring, VKAs are associated with more bleeding complications than LMWH therapies.[9](#rth212002-bib-0009){ref-type="ref"}, [10](#rth212002-bib-0010){ref-type="ref"}, [11](#rth212002-bib-0011){ref-type="ref"}

A recent meta‐analysis of randomized controlled trials also found that direct oral anticoagulants (DOACs) were as effective and safe as warfarin for the treatment of VTE among patients with cancer.[12](#rth212002-bib-0012){ref-type="ref"} In this population, a recent subgroup analysis of the EINSTEIN‐DVT and PE randomized clinical trial comparing rivaroxaban to VKAs showed that a single‐drug approach with the DOAC rivaroxaban resulted in similar efficacy and safety to VKAs.[13](#rth212002-bib-0013){ref-type="ref"}

Little is known about the current utilization of anticoagulant agents in patients with cancer after the approval of DOAC treatments in recent years. The aim of the current study was to describe current treatment patterns and to evaluate patients' persistence to anticoagulant agents.

2. METHODS {#rth212002-sec-0008}
==========

2.1. Data source {#rth212002-sec-0009}
----------------

Medical and pharmacy claims from the Humana Database from January 2007 to December 2014 were used to conduct the analysis. The Humana database includes over 18 million covered lives of commercial and Medicare members in all census regions in the United States, but predominantly in the Midwest and South regions. Over 9 million members have both medical and pharmacy coverage. The present study used data elements from commercial and Medicare Advantage Part D (MA‐PD) members, such as demographics, enrollment history, inpatient and outpatient claims, emergency department visits, and pharmacy claims. Data were de‐identified and data collection complied with the requirements of the Health Insurance Portability and Accountability Act (HIPAA).

2.2. Study design {#rth212002-sec-0010}
-----------------

A retrospective cohort design was used to describe current treatment patterns and to evaluate persistence to therapy on various anticoagulants. Newly diagnosed patients with cancer were identified with at least 1 inpatient stay or 2 outpatient visits with a diagnosis of cancer during the study period (from January 2007 to December 2014). Patients with a first VTE diagnosis (index VTE) in 2013 or 2014 were identified to reflect current prescribing patterns of anticoagulant treatments (the approval date of rivaroxaban for treatment of VTE was November 2012).[14](#rth212002-bib-0014){ref-type="ref"} The index VTE had to occur 30 days before or any time after first cancer diagnosis. A 30‐day window before the cancer diagnosis was allowed to account for VTE as an early sign of cancer. Patients who received one or more anticoagulant prescription claims within 30 days after their VTE diagnosis were selected. Patients were required to have at least 6 months of baseline data prior to the index VTE. Patients with a prior history of VTE or anticoagulation before cancer and patients with a prior dispensing of an anticoagulant before the index VTE were excluded from the study.

Focusing on the most commonly prescribed anticoagulants, patients were classified into LMWH, warfarin, and rivaroxaban cohorts based on the first anticoagulant received. The only exception is the warfarin cohort, which represents patients who either initiated on warfarin alone or who received LMWH during a short duration, as a bridging agent. Use of other anticoagulants, including fondaparinux, heparin, apixaban, or dabigatran, was low and could not be analyzed due to the small sample size.

The observation period (follow‐up) spanned from the date of the first anticoagulant dispensing to the end of insurance eligibility, death, or the end of data availability (December 2014), whichever occurred earlier.

2.3. Study endpoints {#rth212002-sec-0011}
--------------------

Persistence on therapy was evaluated as continuous treatment on the index therapy, defined as no gap of more than 60 days between the end of a dispensing days of supply and the start date of the next dispensing, if any. The treatment duration was therefore calculated from the start date of the first dispensing of the index therapy until treatment non‐persistence, (not including the 60‐day gap) or the end of the follow‐up period.

2.4. Statistical analysis {#rth212002-sec-0012}
-------------------------

Patient characteristics were summarized by treatment cohorts (ie, LMWH, warfarin, and rivaroxaban users). Descriptive statistics, including mean (standard deviation \[SD\]) for continuous data and relative frequency for categorical data, were generated to describe the baseline characteristics of the different treatment cohorts. Statistical differences between cohorts were assessed using Chi‐square tests (categorical variables) and Student\'s *t* tests (continuous variables). Patient characteristics were assessed during the 6‐month baseline period prior to the index VTE. The type of index cancer was also reported and may have occurred before the 6‐month baseline period.

Kaplan‐Meier survival analyses at 6 and 12 months were performed to evaluate and compare time to discontinuation between groups. Multivariate Cox proportional hazard models (ie, time to event analysis) were used to compare the time to discontinuation between cohorts. Covariates for the adjusted models included age, sex, cancer type, region, race, calendar quarter of first VTE (eg, 2013Q1), setting in which the VTE was diagnosed (inpatient, outpatient, or emergency department), type of VTE (DVT, PE, or both), Charlson comorbidity index (CCI), and health care costs during the 6‐month baseline period before the index VTE. In addition, surgeries (ie, major surgery,[15](#rth212002-bib-0015){ref-type="ref"}, [16](#rth212002-bib-0016){ref-type="ref"}, [17](#rth212002-bib-0017){ref-type="ref"} abdominal surgery, and surgery‐provoked VTE \[ie, neurosurgery or orthopedic surgery\]) and other type of provoked VTEs (ie, trauma, acute spinal cord injury, fracture, estrogen therapy, pregnancy/postpartum state, or oral contraceptive use)[15](#rth212002-bib-0015){ref-type="ref"} in the 30 days prior to the index date were also included as covariates in the model.

Since the number of days of supply of the first refill for oral anticoagulants is usually longer than for injectable anticoagulants, a sensitivity analysis was performed on the subset of patients treated for at least 30 days, thus excluding patients who received an initial treatment of a short duration. This sensitivity analysis assessed whether the differences in persistence between patients treated with injectable anticoagulants vs oral anticoagulants may have been inflated by the higher number of days of supplies of oral anticoagulant dispensings.

All statistical analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA).

3. RESULTS {#rth212002-sec-0013}
==========

3.1. Patients characteristics {#rth212002-sec-0014}
-----------------------------

A total of 2941 newly diagnosed VTE patients with cancer who were treated with anticoagulant agents were identified. Of these, 97% received anticoagulation with either LMWH (n = 735; 25%), warfarin (n = 1403; 47.7%), or rivaroxaban (n = 709; 24.1%; Table [1](#rth212002-tbl-0001){ref-type="table"}). Mean age and gender were similar across treatment cohorts. Approximately 90% of patients had primary diagnoses of solid tumors. Diagnoses for DVT, PE, and both DVT and PE (DVT/PE) were 55%, 27%, and 18%, respectively, and were similar across the drug cohorts. Patients with cancers associated with very high VTE risk (ie, stomach, pancreas, and brain) ranged from 15% in LMWH to 7.8% in rivaroxaban cohorts, while cancers associated with high VTE risk (ie, lung, lymphoma, gynecologic, bladder, testicular, and renal) ranged from 38% in LMWH to 28% in warfarin cohort.

###### 

Patient Characteristics

                                                                                                             LMWH \[A\]             Warfarin \[B\]         Rivaroxaban \[C\]     *P*‐values[a](#rth212002-note-0002){ref-type="fn"}   
  ---------------------------------------------------------------------------------------------------------- ---------------------- ---------------------- --------------------- ---------------------------------------------------- --------
  Age, mean (SD) \[median\]                                                                                  71.2 (10.4) \[71.0\]   73.3 (10.5) \[73.0\]   73.3 (9.5) \[73.0\]   \<.001                                               \<.001
  Gender, female, n (%)                                                                                      389 (52.9)             699 (49.8)             353 (49.8)            .173                                                 .233
  Race/Ethnicity, n (%)                                                                                                                                                                                                               
  White                                                                                                      534 (72.7)             1092 (77.8)            567 (80.0)            .008                                                 .001
  Black                                                                                                      101 (13.7)             202 (14.4)             79 (11.1)             .679                                                 .135
  Hispanic                                                                                                   7 (1.0)                9 (0.6)                6 (0.8)               .428                                                 .831
  Other                                                                                                      17 (2.3)               21 (1.5)               10 (1.4)              .175                                                 .206
  Unknown                                                                                                    76 (10.3)              79 (5.6)               47 (6.6)              \<.001                                               .012
  Region,[b](#rth212002-note-0003){ref-type="fn"} n (%)                                                                                                                                                                               
  South                                                                                                      406 (55.2)             779 (55.5)             483 (68.1)            .900                                                 \<.001
  Midwest                                                                                                    227 (30.9)             414 (29.5)             151 (21.3)            .509                                                 \<.001
  Northeast                                                                                                  26 (3.5)               33 (2.4)               11 (1.6)              .122                                                 .399
  West                                                                                                       76 (10.3)              177 (12.6)             64 (9.0)              .112                                                 .017
  Type of primary cancer,[b](#rth212002-note-0003){ref-type="fn"} n (%)                                                                                                                                                               
  Solid cancer                                                                                               675 (91.8)             1,244 (88.7)           633 (89.3)            .022                                                 .096
  Lung                                                                                                       154 (21.0)             216 (15.4)             139 (19.6)            .001                                                 .525
  Prostate                                                                                                   44 (6.0)               191 (13.6)             91 (12.8)             \<.001                                               \<.001
  Breast                                                                                                     50 (6.8)               181 (12.9)             87 (12.3)             \<.001                                               \<.001
  Colorectal                                                                                                 98 (13.3)              166 (11.8)             84 (11.8)             .316                                                 .395
  Other solid cancer                                                                                         329 (44.8)             490 (34.9)             232 (32.7)            \<.001                                               \<.001
  Hematologic cancer                                                                                         70 (9.5)               161 (11.5)             93 (10.9)             .167                                                 .823
  Time from cancer to first VTE, n (%)                                                                                                                                                                                                
  Less than 6 months                                                                                         496 (67.5)             736 (52.5)             350 (49.4)            \<.001                                               \<.001
  6 months to 1 year                                                                                         79 (10.7)              175 (12.5)             89 (12.6)             .242                                                 .285
  More than 1 year                                                                                           160 (21.8)             492 (35.1)             270 (38.1)            \<.001                                               \<.001
  Type of index VTE, n (%)                                                                                                                                                                                                            
  PE                                                                                                         200 (27.2)             367 (26.2)             200 (28.2)            .600                                                 .672
  DVT                                                                                                        395 (53.7)             782 (55.7)             393 (55.4)            .378                                                 .519
  PE and DVT                                                                                                 140 (19.0)             254 (18.1)             116 (16.4)            .593                                                 .181
  Index VTE                                                                                                                                                                                                                           
  Hospitalization, n (%)                                                                                     459 (62.4)             950 (67.7)             424 (59.8)            .015                                                 .302
  LOS (days), mean (SD) \[median\]                                                                           6.4 (4.9) \[5.0\]      7.6 (5.9) \[6.0\]      5.9 (4.8) \[5.0\]     \<.001                                               .099
  Outpatient, n (%)                                                                                          194 (26.4)             320 (22.8)             189 (26.7)            .065                                                 .910
  Emergency department, n (%)                                                                                82 (11.2)              133 (9.5)              96 (13.5)             .221                                                 .168
  VTE risk by cancer type at baseline,[c](#rth212002-note-0004){ref-type="fn"} n (%)                                                                                                                                                  
  Very high risk[d](#rth212002-note-0005){ref-type="fn"}                                                     110 (15.0)             133 (9.5)              55 (7.8)              \<.001                                               \<.001
  High risk[e](#rth212002-note-0006){ref-type="fn"}                                                          282 (38.4)             387 (27.6)             226 (31.9)            \<.001                                               .010
  Antineoplastic use at baseline,[c](#rth212002-note-0004){ref-type="fn"} n (%)                              92 (12.5)              186 (13.3)             104 (14.7)            .629                                                 .233
  Quan‐Charlson comorbidity index,[c](#rth212002-note-0004){ref-type="fn"} mean (SD) \[median\]              5.0 (3.1) \[6.0\]      4.6 (3.0) \[4.0\]      4.2 (2.9) \[4.0\]     .001                                                 \<.001
  Selected baseline comorbidities,[c](#rth212002-note-0004){ref-type="fn"} n (%)                                                                                                                                                      
  Hypertension                                                                                               486 (66.1)             1,057 (75.3)           503 (70.9)            \<.001                                               .143
  COPD                                                                                                       181 (24.6)             435 (31.0)             220 (31.0)            .008                                                 .025
  Diabetes                                                                                                   202 (27.5)             438 (31.2)             207 (29.2)            .199                                                 .733
  Congestive heart failure                                                                                   80 (10.9)              221 (15.8)             106 (15.0)            .009                                                 .068
  Liver diseases                                                                                             161 (21.9)             179 (12.8)             90 (12.7)             \<.001                                               \<.001
  Obesity                                                                                                    77 (10.5)              172 (12.3)             73 (10.3)             .474                                                 .927
  Atrial fibrillation/flutter                                                                                43 (5.9)               128 (9.1)              69 (9.7)              .030                                                 .022
  Stroke/TIA                                                                                                 42 (5.7)               103 (7.3)              36 (5.1)              .364                                                 .805
  Provoked VTE[f](#rth212002-note-0007){ref-type="fn"} ^,^ [g](#rth212002-note-0008){ref-type="fn"}, n (%)   79 (10.7)              180 (12.8)             74 (10.4)             .161                                                 .848
  Prior surgery[f](#rth212002-note-0007){ref-type="fn"}, n (%)                                                                                                                                                                        
  Major surgery                                                                                              138 (18.8)             279 (19.9)             108 (15.2)            .538                                                 .073
  Abdominal                                                                                                  190 (25.9)             296 (21.1)             113 (15.9)            .013                                                 \<.001
  Surgery‐provoked VTE[h](#rth212002-note-0009){ref-type="fn"}                                               13 (1.8)               47 (3.3)               20 (2.8)              .035                                                 .181

COPD = chronic obstructive pulmonary disease; DVT = deep vein thrombosis; LMWH = low--molecular‐weight heparin; LOS = length of stay; PE = pulmonary embolism; SD = standard deviation; TIA = transient ischemic attack; VTE = venous thromboembolism.

*P*‐values were estimated using Student *t* tests for continuous variables and Chi‐squared tests for categorical variables.

Not mutually exclusive.

Evaluated during the 6‐month baseline period.

Stomach, pancreas, or brain tumor.

Lung, lymphoma, gynecologic, bladder, testicular, or renal cancer.

Evaluated during the 30‐day period prior to the index VTE.

Defined as an index VTE with trauma, acute spinal cord injury, fracture, estrogen therapy, pregnancy/postpartum state, oral contraceptive use, neurosurgery or orthopedic surgery.

Defined as an index VTE with neurosurgery or orthopedic surgery.

John Wiley & Sons, Ltd

Approximately 68% (warfarin) to 58% (rivaroxaban) of VTE cases were diagnosed in the inpatient setting. Overall, patients treated with LMWH had significantly more comorbidities compared to warfarin and rivaroxaban cohorts as shown by the Quan‐Charlson comorbidity index scores (5.0 vs 4.6 and 4.2, respectively; *P*‐values: \<.05). Furthermore, patients in the LMWH cohort had significantly more liver disease (21.9%; *P*‐values: \<.05), and significantly less atrial fibrillation (5.9%; *P*‐values: \<.05) compared to the warfarin and rivaroxaban cohorts (Table [1](#rth212002-tbl-0001){ref-type="table"}). A similar proportion of patients in the 3 cohorts had provoked VTEs (10‐13%) and major surgery (15‐20%) in the 30 days prior to the index date. LMWH users had significantly more abdominal surgeries (26%) compared to patients treated with warfarin (21%) or rivaroxaban (16%), and significantly less surgery provoked‐VTE (1.8%) compared to warfarin (3.3%; Table [1](#rth212002-tbl-0001){ref-type="table"}).

3.2. Treatment patterns and persistence on anticoagulant therapy {#rth212002-sec-0015}
----------------------------------------------------------------

The median follow‐up period was relatively short in all cohorts, ranging from 4.7 months in the LMWH cohort to 7.1 months in the warfarin cohort. Around one‐third of the patients died during the follow‐up period: 331 (45.0%), 475 (33.9%), and 219 (30.9%) patients in the LMWH, warfarin, and rivaroxaban cohorts, respectively. Over 60% of patients received anticoagulant treatment in outpatient settings within 7 days post VTE diagnosis (Table [2](#rth212002-tbl-0002){ref-type="table"}). Approximately one‐quarter of patients who initiated LMWH switched to another anticoagulant therapy, while lower switching rates of 8% and 5% were observed for warfarin and rivaroxaban, respectively (Figure [1](#rth212002-fig-0001){ref-type="fig"}).

###### 

Treatment Patterns and Mortality During the Study Period

  Treatment patterns                                                                                           LMWH          Warfarin      Rivaroxaban
  ------------------------------------------------------------------------------------------------------------ ------------- ------------- -------------
  Eligibility post VTE, months, mean \[median\]                                                                6.9 \[4.7\]   8.9 \[7.1\]   6.9 \[5.2\]
  Time from first VTE to therapy, days, mean \[median\]                                                        6.6 \[4.0\]   8.0 \[6.0\]   6.1 \[4.0\]
  0‐7 days, n (%)                                                                                              516 (70.2)    845 (60.2)    526 (74.2)
  7‐14 days, n (%)                                                                                             137 (18.6)    321 (22.9)    101 (14.2)
  14‐30 days, n (%)                                                                                            80 (10.9)     232 (16.5)    77 (10.9)
  Died during follow‐up, n (%)                                                                                 331 (45.0)    475 (33.9)    219 (30.9)
  Initiated a new anticoagulant therapy after discontinuation,[a](#rth212002-note-0011){ref-type="fn"} n (%)   71 (9.7)      94 (6.7)      39 (5.5)

LMWH = low--molecular‐weight heparin; VTE = venous thromboembolism.

Discontinuation was defined as a gap of more than 60 days between the end of the days of supply of a dispensing and the start date of the next dispensing of the index therapy, if any.

John Wiley & Sons, Ltd

![Patterns of anticoagulant transition. \*Includes apixaban, dabigatran, fondaparinux, and other combinations](RTH2-1-14-g001){#rth212002-fig-0001}

Patients treated with LMWH were less persistent on therapy compared to other treatment groups. Persistence with the initial therapy at 6 and 12 months, respectively, was 37% and 21% for LMWH users, 61% and 35% for warfarin users, and 61% and 36% for rivaroxaban users (Figure [2](#rth212002-fig-0002){ref-type="fig"}). The corresponding median treatment duration was 3.3 months for LMWH users and 7.9 months for warfarin and rivaroxaban users. Compared to LMWH users, users of oral agents were significantly less likely to discontinue therapy, with hazard ratios (HRs; 95% confidence interval \[CI\]) of 0.33 (0.28‐0.38) for warfarin users and 0.38 (0.32‐0.46) for rivaroxaban users (Figure [3](#rth212002-fig-0003){ref-type="fig"}).

![Persistence on index therapy. (Discontinuation was defined as a gap of more than 60 days between the end of the days of supply of a dispensing and the start date of the next dispensing of the index therapy, if any)](RTH2-1-14-g002){#rth212002-fig-0002}

![Adjusted risk of discontinuation of the index therapy.^1^\
*Note*: Adjusted for age, sex, cancer type, region, race, calendar quarter of first venous thromboembolism (VTE) (eg, 2013Q1), setting in which the VTE was diagnosed (inpatient, outpatient, or emergency department), type of VTE (deep vein thrombosis, pulmonary embolism, or both), Charlson comorbidity index (CCI), and health care costs during the 6‐month period before the index VTE, and surgeries (ie, major surgery, abdominal surgery, and surgery‐provoked VTE) and other types of provoked VTEs in the 30 days prior to the index VTE](RTH2-1-14-g003){#rth212002-fig-0003}

The sensitivity analysis performed on the subset of patients persistent for at least 30 days on the initial anticoagulant included a total of 453, 1268, and 597 patients in the LMWH, warfarin, and rivaroxaban cohorts, respectively. This sensitivity analysis only included patients treated for the standard refill of an oral warfarin prescription (ie, 30 days). The median duration of therapy was 6.0, 8.3, and 8.5 months in the LMWH, warfarin, and rivaroxaban cohorts respectively. In the sensitivity analysis (ie, patients treated for at least 30 days), LMWH/warfarin, warfarin, and rivaroxaban users were still significantly less likely to discontinue therapy compared to LMWH users, with adjusted HRs (95% CI) of 0.64 (0.53‐0.77) for the warfarin users and 0.65 (0.52‐0.82) for rivaroxaban users.

4. DISCUSSION {#rth212002-sec-0016}
=============

A large medical and pharmacy claims database was used to describe current treatment patterns and assess patient persistence on anticoagulant therapies for cancer‐associated thrombosis. Despite treatment guidelines, recommendations for the use of LMWH monotherapy for the treatment of and as secondary prophylaxis for VTE, over 70% of patients were treated with oral anticoagulants. Patients initiating with LMWH treatment persisted significantly shorter and were significantly more likely to discontinue the treatment relative to patients treated with warfarin or rivaroxaban. Approximately one‐quarter of patients who initiated on LMWH switched to other anticoagulant agents during the course of treatment compared to 8% and 5% patients observed with warfarin and rivaroxaban, respectively.

Since the publication of the CLOT study[7](#rth212002-bib-0007){ref-type="ref"} that demonstrated LMWH superiority over warfarin in a randomized control trial evaluating the risk of reoccurrence of VTE in cancer patients, guidelines started to recommend LMWH therapy over warfarin. Currently, all major guidelines, including the American College of Chest Physicians (ACCP),[5](#rth212002-bib-0005){ref-type="ref"} the American Society of Clinical Oncology (ASCO),[4](#rth212002-bib-0004){ref-type="ref"} the National Comprehensive Cancer Network (NCCN),[18](#rth212002-bib-0018){ref-type="ref"} and the European Society for Medical Oncology (ESMO),[11](#rth212002-bib-0011){ref-type="ref"} recommend LMWH for the treatment of VTE and as secondary prophylaxis in patients with cancer. Despite promising results for DOAC in cancer patients,[12](#rth212002-bib-0012){ref-type="ref"}, [19](#rth212002-bib-0019){ref-type="ref"} use of DOACs for either prevention or treatment of VTE in cancer patients is not recommended at the time[4](#rth212002-bib-0004){ref-type="ref"} based on a lack of evidence of efficacy and safety in patients with cancer.

In the current study, only 25% of patients were treated with a LMWH therapy as a single agent. The risk of discontinuation in these patients was significantly higher than in oral treatments. The low use of LMWH in cancer patients was observed in multiple other studies. Delate and colleagues[20](#rth212002-bib-0020){ref-type="ref"} observed that the use of LMWH only increased from 18% in 2000 to 31% in 2007 after the recommendations by the ACCP. Farge and colleagues[21](#rth212002-bib-0021){ref-type="ref"} reported that LMWH was used in 36% of patients in early maintenance (11‐90 days) and in 41% of patients for long‐term therapy (beyond 3 months). A few studies have identified reasons for the low utilization or discontinuation on LMWH. Even though physicians are aware of the guideline recommendations,[22](#rth212002-bib-0022){ref-type="ref"} reasons for noncompliance included: patients could not afford the out‐of‐pocket expense, the referring physician preferred that the patient received warfarin instead of LMWH therapies, or patients refused the long‐term use of injections.[23](#rth212002-bib-0023){ref-type="ref"}

The current results showed that persistence on the initial anticoagulant therapy in cancer patients is very low in patients treated with initial LMWH. The persistence rate at 6 months was 37% for patients treated with LMWH and 61% for patients treated with oral therapies. Studies on persistence with anticoagulant therapy in cancer patients are limited, but similar real‐world studies also found that patients receiving injectable anticoagulants were less persistent than those treated with oral anticoagulants.[24](#rth212002-bib-0024){ref-type="ref"} This might also reflect the treatment patterns of physicians, prescribing LMWH for only short periods despite treatment recommendations among active cancer patients. Additionally, in patients with risk factors for VTE, including patients with cancer‐related VTE, adherence on warfarin was also reported to be low: 77% of patients treated with warfarin had a proportion of days covered lower than 0.8 during the year after initiation of therapy.[25](#rth212002-bib-0025){ref-type="ref"}

The low persistence observed with LMWH is further reflected in the high‐switching rates from LMWH to other anticoagulants. In a previous study of 52,911 patients with cancer who were treated with an anticoagulant, 44% of the 21,164 patients treated with LMWH switched to another anticoagulant and 28% of the 26,456 patients treated with warfarin switched to another anticoagulant.[24](#rth212002-bib-0024){ref-type="ref"} The percentage of patients who switched in the current study was lower than what was reported in these other studies. This may be related to the shorter follow‐up in the current study due to our focus on a study population with VTE diagnosed after 2013.

This retrospective cohort analysis has certain limitations. First, in spite of information accuracy and completeness required by administrative databases for payment purposes, billing inaccuracies and missing data may still occur. Second, there were no data on patient adherence, and we assumed that medications supplied were actually used by the patients, which could have led to an overestimation of patients' adherence. Third, the observational design was susceptible to biases such as information or classification bias (eg, identification of false‐positive VTE events). It is also possible that VTE events were under‐coded (ie, false‐negative). Finally, like all observational studies, adjustments in the multivariate analyses could only account for observable factors. For example, information on remission for patients who completed all cancer treatment was not available in the database which could impact the rate of adherence if anticoagulation therapy was discontinued due to remission. However, we do not have reasons to believe that this would have affected the findings since LMWH is frequently used in high‐risk settings[24](#rth212002-bib-0024){ref-type="ref"} and patients with lower risk for recurrent VTE may be less likely to receive LMWH, which suggests that the LMWH group may have had a longer duration of intended therapy if there was a difference in the remission status among the 3 groups. Despite these limitations, the current study has several strengths, including reliance on the real‐world utilization of LMWH, warfarin, and rivaroxaban use in patients with cancer, and it is consistent with prior similar analyses.

This real‐world analysis of current treatment patterns for cancer‐associated thrombosis showed that warfarin is still the most commonly used anticoagulant and that rivaroxaban is as commonly used as LMWH, despite guideline recommendations. Patients on LMWH had a significantly lower persistence and a shorter duration of treatment than patients on warfarin or rivaroxaban during the course of treatment. Patients initiating on these oral agents are at significantly lower risk to discontinue therapy relative to LMWH. Furthermore, more patients switched from LMWH to other anticoagulants compared with patients who had started on warfarin or rivaroxaban treatments.
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